CS Group Announces the Valuation of MEDUSA Surface Disinfectant at USD 513 Million
-
Eli Crane Defeats Jonathan Nez in Tight Arizona Congressional Race
-
David Walliams Identified as Celebrity in Sexual Misconduct Allegations After Legal Bid
-
Sherilyn Smith Encourages Women to Embrace Scars as Symbols of Resilience
-
Korea's Severe Asthma Patients Blocked from Biologics by Restrictive Reimbursement Rules
-
Belgium Signs Contract for 20 Rheinmetall Skyranger Air Defence Systems
-
Shanghai Science and Technology Museum Signs Pacts With London and Ottawa Institutions at CIIE
-
Four Nines Gold Intersects 67 Metres at 1.78 g/t Gold, Reinforing Emerging Gold Corridor at Hayden Hill
-
New Gold IRA Investing Guide Explains How to Buy Gold in an IRA for American Consumers
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 10
-
Fulcrum Metals PLC Announces Fulcrum to Increase Shareholding in Loyalist
-
Spectrocell Strengthens Product Discovery and Customer Engagement with Bioz Badges
-
3D Induced Polarization Survey Identifies a Large Drill Target at East Goldfield
-
Apex Extends Trinity Zone in West Step-out Drilling With 2.52% REO Over 223.3 m and 2.49% REO Over 123.3 m at Rift
-
KIFFIK Biomedical Recognized as Top Biomarker Access Technology 2026 by Life Sciences Review
-
Zomedica Announces "Third Friday at Four" Webinar on November 20, 2026: The People Behind Zomedica - Seven Guiding Principles in Action, and Q3 Financial Results
-
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
-
Geek+ Unveils 24/7 Warehouse Autonomy Plan to Advance Self-Optimizing, Around-the-Clock Operation
-
Gamma Resources Announces Planned Radon Flux Baseline Survey at Mesa Arc Uranium Project in New Mexico, Provides Update on Project Timelines
-
China Explores a New Pathway for Medical AI: Bridging R&D Innovation and Clinical Adoption
-
Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
-
Aztec Drills 70.1 Meters of 0.80 g/t AuEq (0.49 g/t Au and 16.85 g/t Ag) from Surface in TR26-54 at the Tombstone Project, Arizona
-
Silicon Publishing Launches Prism, Bringing AI-Assisted Automation to Database Publishing
-
Zeb Nickel Commences Diamond Drilling at the Zeb Nickel Project
-
Aston Bay Announces Pre-Feasibility Study Results and Maiden Mineral Reserve for the Storm Copper Project, Nunavut
-
Electrovaya to Participate in Upcoming Investor Conferences
-
Moderna to Present at Upcoming Conference in November 2026
-
INEO Invited to 15th Annual ROTH Technology Conference in New York
-
Odyssey Behavioral Healthcare Launches Virtual Intensive Outpatient Mental Health Treatment for Adults
-
Nextech3D.ai to Report Fiscal Second Quarter 2027 Financial Results and Host Investor Webinar on November 19, 2026 at 4:30 PM ET
-
Adcore Reports Third Quarter 2026 Results: Gross Margin Rises to 64%, Operating Loss Halved, Cash Up to $4.3 Million as Restructuring Takes Hold
-
Sterling Metals Announces Fully Allocated Private Placement of Units, Flow-Through Shares and Charity Flow-Through Units
-
Wash100 Award, GovCon Industry's Highest Honor, Opens Nominations for 2027 Season
-
Greene Concepts Highlights Groundwater Resources and Commercial Opportunities
-
SNZweig Forms AEC Industry Advisory Council
-
Allstar Health Brands Confirms MLS NEXT Expansion Bid to Anchor a Permanent Training Structure and a Professional Pathway
-
BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
-
Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations
-
Horizon Aircraft Completes Preliminary Design Review of Cavorite X7 Hybrid eVTOL
-
Cardiff Lexington To Report Third Quarter 2026 Financial Results and Host Conference Call on Monday, November 16, 2026
-
ATWEC Technologies, Inc. (OTCID:ATWT) Reports Third Quarter 2026 Revenue of $12.46 Million, Up 37% Year-over-Year
-
ByNext Joins the Bilt Neighborhood: Reaching More Customers by Integrating Its Technology with Bilt Neighborhood OS
-
Your Patients Are Asking AI About You. AimwellBio Lets Every Physician See the Answer, Free.
-
Peraso to Showcase DUNE 60 GHz Wireless Platform at Africa Tech Festival 2026
-
Jerash Holdings Reports Fiscal 2027 Second Quarter Financial Results
-
SMX Advances Development of its Scientific Intelligence, an AI-Powered Platform Intended to Create a Comprehensive Codex for Chemical Agents, Additives and Supplements
-
Innovative Menopause Medicine from JASTLabs Advances Patent Protection Internationally
-
Kalm with Kava and Pū'iwa Farms Hawai'i Bring Fresh Frozen Hawaiian Kava to Market
-
ClearSign Receives Order for "M1" Series Burner from Tulsa Heaters Midstream (THM)
-
Berwyn Group Launches BerwynAPI, Bringing Real-Time Death Confirmation to a Broad Variety of Industries Including Financial Services, Insurance and Healthcare
-
Team Montlick Wins Class 2 World Championship Title in Key West
CS Group Announces the Valuation of MEDUSA Surface Disinfectant at USD 513 Million
CHEYENNE, WY AND NEUSS, GERMANY / ACCESS Newswire / April 22, 2025 / CS Group announced the completion of a comprehensive valuation for its proprietary smart surface disinfectant, MEDUSA. The valuation conducted as of April 1, 2025 estimates the fair market value of these rights at USD 513 Million reflecting the significant growth potential and competitive advantages of the MEDUSA product line.
CS Group is advancing discussions with healthcare providers, facilities management companies, and distribution partners that cover North America, Europe, the Middle East, Africa, and Asia/Pacific to accelerate market entry and bring MEDUSA to global audiences.
The surface disinfectant market is expected to grow from USD 5.46 Billion in 2023 to USD 8.84 Billion by 2030 driven by heightened awareness of infection prevention. CS Group's strategic valuation estimates MEDUSA can capture up to 3% market share by 2030 through focused B2B and retail channel expansion.
Thomas Fahrhöfer, President of the Board at CS Diagnostics Corp. mentioned:
"Where competitors sell volume through frequent reapplication, we deliver efficiency through lasting protection. This translates to real cost savings for facility managers and a superior value proposition in the market "
Mohammad EsSayed, Vice President of the Board at CS Diagnostics Corp., commented:
"MEDUSA requires reduced application frequency in high-traffic environments delivering cost and labour savings. With regulatory approvals progressing and a clear path to commercialization, we are confident that MEDUSA can capture meaningful market share while delivering value to our partners and end-users."
About MEDUSA
MEDUSA (https://medusa-sdp.com/) is a Smart disinfectant Product designed to meet the highest standards of hygiene and safety. From rapid-acting Alcohol-based formulas to gentle Alcohol-free options, MEDUSA delivers robust protection, uncompromising efficacy, and eco-conscious formulas to safeguard your spaces.
Proven Effectiveness Against:
Bacteria: Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Enterococcus hirae
Fungi: Candida Albicans
Viruses: SARS-COV2, Covid families, Influenza families, and various Enveloped viruses
About CS Diagnostics Corp.
CS Diagnostic Corp. is a global healthcare innovation company committed to advancing medical diagnostics through innovation and precision technology. With a strong foundation in research and a global vision, the company delivers cutting-edge solutions to meet the evolving needs of the healthcare industry.
Forward-Looking Statements
This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.
Actual results achieved may vary from the information provided herein because of numerous known and unknown risks and uncertainties and other factors.
For further information please visit: https://csinterpharm.ae/wp-content/uploads/2025/04/MEDUSA-Evaluation.pdf, https://medusa-sdp.com/, https://csdcorp.us/ or email: [email protected]
SOURCE: CS Diagnostics Corp.
View the original press release on ACCESS Newswire
Y.Kobayashi--AMWN